SCHEMBL1108568

SCHEMBL1108568

CN(C[C@@H]1NC(=O)NC1=O)S(=O)(=O)c1ccc(Oc2ccc(Cl)cn2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.40
PTGS1 P23219 2/20 0.40
PTGS2 P35354 2/20 0.40
DAGLA Q9Y4D2 1/20 0.39
PSEN1 P49768 5/20 0.38
PSEN2 P49810 5/20 0.38
APH1B Q8WW43 5/20 0.38
NCSTN Q92542 5/20 0.38
APH1A Q96BI3 5/20 0.38
PSENEN Q9NZ42 5/20 0.38
PGR P06401 1/20 0.35
UCHL1 P09936 1/20 0.35
USP30 Q70CQ3 1/20 0.35
MMP2 P08253 4/20 0.34
MMP9 P14780 4/20 0.34
CYP3A4 P08684 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100372 1.00 LIPE (0.40) LIPEPTGS1PTGS2DAGLAPSEN1
SCHEMBL1108572 0.88 LMNA (0.43) LIPEPTGS1PTGS2DAGLAPSEN1
SCHEMBL1100382 0.88 LMNA (0.43) LIPEPTGS1PTGS2DAGLAPSEN1
SCHEMBL1108503 0.87 PGR (0.46) DAGLAPSEN1PSEN2APH1BNCSTN
SCHEMBL1098732 0.87 PGR (0.46) DAGLAPSEN1PSEN2APH1BNCSTN
SCHEMBL1108514 0.85 MMP2 (0.39) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL1108520 0.82 USP30 (0.40) LIPEPTGS1PTGS2DAGLAPGR
SCHEMBL1099709 0.82 USP30 (0.40) LIPEPTGS1PTGS2DAGLAPGR
SCHEMBL1101042 0.81 LMNA (0.40) PTGS2PSEN1PSEN2APH1BNCSTN
SCHEMBL1108565 0.81 LMNA (0.40) PTGS2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LIPE 4387/4885PTGS1 124/4885PTGS2 235/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 LIPE 4387/4885PTGS1 124/4885PTGS2 235/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 LIPE 3793/4885PTGS1 167/4885PTGS2 188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.